The Idea

To date, mucosal healing should be the therapeutic goal in inflammatory bowel disease (IBD), as it is associated with sustained clinical remission, reduced rates of hospitalization and operations, as well as a lower incidence of colorectal cancer. We have developed the a multi-immune pathway biomarker test that identifies mucosal healing in IBD patients as early as 3-6 weeks following treatment initiation.

The Technology

To address the various challenges in identifying fast and accurate endoscopic response in clinical practice, as well as the clinical development of novel Ulcerative colitis therapies, Kepler Diagnostics has developed the UCRI: a unitless multi-immune pathway biomarker test as a surrogate marker for endoscopic response. The UCRI is based on a solid analysis of more than then 10 different innate-immunity and inflammatory biomarkers from different immune pathways.

  • Ensure enrollment of an appropriate Ulcerative Colitis patient population

  • Identify Ulcerative Colitis patients with high disease activity

  • Use a simple blood test as a surrogate marker to detect endoscopic response to treatment in UC

  • Detect endoscopic response within few weeks

  • Use the UCRI for new therapeutic agent dose selection

Scientific Publications
Advisory Board
Charalabos Pothoulakis, M.D.
Director, Basic Research, UCLA Center for Inflammatory Bowel Diseases
Director, Center for Systems Biomedicine
Director, Research Integration
Director, Integrated Molecular Technologies CURE & Vector Cores at UCLA
Professor of Medicine, Pathology and Laboratory Medicine Eli and Edythe Broad Chair in Medicine
Vatche and Tamar Manoukian Division of Digestive Diseases David Geffen School of Medicine at UCLA